Brief Summary
The aim of this project is to evaluate the Safety of Immune Cellsthe basic structural and functional unit of all living things for Patients with Relapsed Leukaemiacancer of blood and/or blood forming tissues or Lymphomacancers of the lymphatic system after Bone Marrow Transplanta procedure that involves replacing unhealthy bone marrow with healthy bone marrow.
Intervention/Treatment
- Stem cell transplanta procedure that involves replacing unhealthy blood-forming cells (stem cells) with healthy stem cells of CAR19 T-cells
- Drug: Lymphodepleting cyclophosphamide
- Drug: Fludarabine
Inclusion Criteria
- Any patient regardless of sex or age with persistent or recurrent disease after a matched related allogeneic stem cell transplant performed for CD19+ lymphoid malignancies. Disease may be identified by clinical examination, radiology, nuclear imagingtests that create detailed images of areas inside the body, flow cytometry or molecular biological methods.
- Life expectancy greater than or equal to 6 weeks.
- Karnofsky/Lansky score greater than or equal to 50%, or ECOG less than or equal to 2.
- Donor willing and available to donate peripheral bloodthe red bodily fluid that transports oxygen and other nutrients around the body for the generation of CAR19 T-cells.
- Sexually active patients must be willing to utilise one of the more effective birth control methods for 6 months after the CTL infusionto slowly introduce/give fluid into a vein. Male partners should use a condom.
- Donor and patient and/or parent/guardian capable of providing informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..